Research programme: T cell-based therapeutics - Opus Bio

Drug Profile

Research programme: T cell-based therapeutics - Opus Bio

Alternative Names: CAR T-cell based therapies; CAR+ T; Chimeric antigen receptor T cell therapies; LG 690

Latest Information Update: 01 Sep 2014

Price : $50

At a glance

  • Originator Lentigen Corporation; University of Pennsylvania
  • Developer Medical University of South Carolina; Opus Bio; University of Pennsylvania
  • Class CAR-T cell therapies
  • Mechanism of Action Apoptosis stimulants; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Leukaemia; Lymphoma; Malignant melanoma

Most Recent Events

  • 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology
  • 14 Aug 2014 Miltenyi Biotec acquires the cell and gene therapy assets of Lentigen Corporation, and forms Lentigen Technology
  • 19 Oct 2006 Lentigen Corporation has received an SBIR grant from the National Institutes of Health to evaluate the concept of using lentiviral-engineered T-cells to improve the efficacy of Cancer immunotherapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top